Literature DB >> 35316583

Validation-Based Insertional Mutagenesis (VBIM), A Powerful Forward Genetic Screening Strategy.

Sarmishtha De1, Ilaria Tamagno2, George R Stark1, Mark W Jackson2.   

Abstract

Forward genetics begins with a biological phenotype and attempts to identify genetic changes that influence that phenotype. These changes can be induced in a selected group of genes, for instance, by using libraries of cDNAs, shRNAs, CRISPR guide RNAs, or genetic suppressor elements (GSEs), or randomly throughout the genome using chemical or insertional mutagens, with each approach creating distinct genetic changes. The Validation-Based Insertional Mutagenesis (VBIM) strategy utilizes modified lentiviruses as insertional mutagens, placing strong promoters throughout the genome. Generating libraries with millions of cells carrying one or a few VBIM promoter insertions is straightforward, allowing selection of cells in which overexpression of VBIM-driven RNAs or proteins promote the phenotype of interest. VBIM-driven RNAs may encode full-length proteins, truncated proteins (which may have wild-type, constitutive, or dominant-negative activity), or antisense RNAs that can disrupt gene expression. The diversity in VBIM-driven changes allows for the identification of both gain-of-function and loss-of-function mutations in a single screen. Additionally, VBIM can target any genomic locus, regardless of whether it is expressed in the cells under study or known to have a biological function, allowing for true whole-genome screens without the complication and cost of constructing, maintaining, and delivering a comprehensive library. Here, we review the VBIM strategy and discuss examples in which VBIM has been successfully used in diverse screens to identify novel genes or novel functions for known genes. In addition, we discuss considerations for transitioning the VBIM strategy to in vivo screens. We hope that other laboratories will be encouraged to use the VBIM strategy to identify genes that influence their phenotypes of interest.
© 2022 Wiley Periodicals LLC. © 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  cell libraries; drug resistance; forward genetics; in vivo screens; insertional mutagenesis; lentiviral vectors

Mesh:

Year:  2022        PMID: 35316583      PMCID: PMC8969887          DOI: 10.1002/cpz1.394

Source DB:  PubMed          Journal:  Curr Protoc        ISSN: 2691-1299


  34 in total

1.  Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Angela DeMichele; Douglas Yee; Laura Esserman
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

2.  Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65.

Authors:  Tao Lu; Mark W Jackson; Benlian Wang; Maojing Yang; Mark R Chance; Masaru Miyagi; Andrei V Gudkov; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

3.  FAM83B mediates EGFR- and RAS-driven oncogenic transformation.

Authors:  Rocky Cipriano; James Graham; Kristy L S Miskimen; Benjamin L Bryson; Ronald C Bruntz; Sarah A Scott; H Alex Brown; George R Stark; Mark W Jackson
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

4.  Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer.

Authors:  Rocky Cipriano; Kristy L S Miskimen; Benjamin L Bryson; Chase R Foy; Courtney A Bartel; Mark W Jackson
Journal:  Mol Cancer Res       Date:  2014-04-15       Impact factor: 5.852

5.  EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.

Authors:  Sarmishtha De; Josephine Kam Tai Dermawan; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

6.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

7.  The landscape of long noncoding RNAs in the human transcriptome.

Authors:  Matthew K Iyer; Yashar S Niknafs; Rohit Malik; Udit Singhal; Anirban Sahu; Yasuyuki Hosono; Terrence R Barrette; John R Prensner; Joseph R Evans; Shuang Zhao; Anton Poliakov; Xuhong Cao; Saravana M Dhanasekaran; Yi-Mi Wu; Dan R Robinson; David G Beer; Felix Y Feng; Hariharan K Iyer; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2015-01-19       Impact factor: 38.330

8.  In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma.

Authors:  Fei Li; Qingyuan Huang; Troy A Luster; Hai Hu; Hua Zhang; Wai-Lung Ng; Alireza Khodadadi-Jamayran; Wei Wang; Ting Chen; Jiehui Deng; Michela Ranieri; Zhaoyuan Fang; Val Pyon; Catríona M Dowling; Ece Bagdatlioglu; Christina Almonte; Kristen Labbe; Heather Silver; Alexandra R Rabin; Kandarp Jani; Aristotelis Tsirigos; Thales Papagiannakopoulos; Peter S Hammerman; Vamsidhar Velcheti; Gordon J Freeman; Jun Qi; George Miller; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2019-11-19       Impact factor: 38.272

9.  SLX4IP and telomere dynamics dictate breast cancer metastasis and therapeutic responsiveness.

Authors:  Nathaniel J Robinson; Chevaun D Morrison-Smith; Alex J Gooding; Barbara J Schiemann; Mark W Jackson; Derek J Taylor; William P Schiemann
Journal:  Life Sci Alliance       Date:  2020-02-18

Review 10.  NF-kappa B: a new player in angiostatic therapy.

Authors:  Sebastien P Tabruyn; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2008-02-19       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.